- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01396785
Topical Antifungal Treatment for Tinea Pedis
August 20, 2013 updated by: Medicis Global Service Corporation
A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Pedis
The purpose of this study is to determine if a topical antifungal cream is safe and effective for the treatment of tinea pedis.
Study Overview
Study Type
Interventional
Enrollment (Actual)
321
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cidra, Puerto Rico
-
-
-
-
California
-
Los Angeles, California, United States
-
-
New Jersey
-
Paramus, New Jersey, United States
-
-
New Mexico
-
Albuquerque, New Mexico, United States
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States
-
-
Texas
-
Austin, Texas, United States
-
College Station, Texas, United States
-
Plano, Texas, United States
-
San Antonio, Texas, United States
-
-
Utah
-
Salt Lake City, Utah, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Moderate erythema, moderate scaling, and mild pruritus
Exclusion Criteria:
- Pregnancy and allergies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active
Product 33525
|
Daily for 14 days
|
Placebo Comparator: Placebo
Product 33525 Placebo
|
Daily for 14 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients achieving complete clearance
Time Frame: Day 42
|
Signs and Symptoms Severity Score and negative Potassium Hydroxide (KOH) and Culture
|
Day 42
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients achieving effective treatment
Time Frame: Day 42
|
Clinical Cure and Mycologic Cure
|
Day 42
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Ron Staugaard, Medicis Pharmaceutical
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2011
Primary Completion (Actual)
January 1, 2012
Study Completion (Actual)
March 1, 2012
Study Registration Dates
First Submitted
July 15, 2011
First Submitted That Met QC Criteria
July 18, 2011
First Posted (Estimate)
July 19, 2011
Study Record Updates
Last Update Posted (Estimate)
August 28, 2013
Last Update Submitted That Met QC Criteria
August 20, 2013
Last Verified
August 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MP-1000-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tinea Pedis
-
National institute of SiddhaCompletedTinea Infections Such as Tinea Corporis, Tinea Cruris, Tinea Pedis, Tinea Mannum, Tinea Barbae, Tinea Capitis Are StudiedIndia
-
Taro Pharmaceuticals USATerminated
-
DermBiont, Inc.TerminatedInterdigital Tinea PedisDominican Republic
-
AmDermaAmDerma Pharmaceuticals, LLCCompletedInterdigital Tinea PedisUnited States
-
Ahmed A. H. AbdellatifUnknownFoot Infection Tinea PedisEgypt
-
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences...CompletedOnychomycosis/Onycholysis and Tinea PedisUnited States
-
Tinea PharmaceuticalsCompletedTinea Pedis | Tinea Cruris | Tinea CorporisUnited States, Puerto Rico, El Salvador, Belize, Honduras
-
Therapeutics, Inc.CompletedTinea Pedis | Tinea CrurisUnited States
-
Bausch & Lomb IncorporatedBausch Health Americas, Inc.CompletedTinea Pedis | Tinea CrurisUnited States
-
Bausch Health Americas, Inc.CompletedTinea Pedis | Tinea CrurisDominican Republic, Honduras
Clinical Trials on 33525
-
Tinea PharmaceuticalsCompletedTinea Pedis | Tinea Cruris | Tinea CorporisUnited States, Puerto Rico, El Salvador, Belize, Honduras
-
Medicis Global Service CorporationCompletedTinea CrurisUnited States, Puerto Rico, Honduras, El Salvador, Belize
-
Medicis Global Service CorporationCompleted
-
Bausch Health Americas, Inc.CompletedTinea CorporisDominican Republic, Honduras